Neutrolis develops new COVID-19 treatment

By The Science Advisory Board staff writers

August 3, 2020 -- Neutrolis has developed a new class of COVID-19 therapy, a DNASEIL3 enzyme analog that has the potential to clear neutrophil extracellular traps (NETs) for severe cases of COVID-19.

The candidate, Ntr-441, is an engineered analog of a natural NET-destroying enzyme encoded by the DNASEIL3 gene. The analog was developed on the company's proprietary Chromatinase platform and is based on a naturally occurring enzyme that breaks down the extracellular chromatin that forms NETs.

Several independent researchers have confirmed that NETs are associated with the clinical severity of COVID-19. Moreover, the company recently published a study in the Lancet's EBioMedicine open-access journal that found NETs in the lungs of COVID-19 patients. The candidate is being developed in part with funding from the National Institutes of Health, and the company plans to pursue testing to evaluate whether Ntr-441 is effective for treating COVID-19.

Are interferons helpful or harmful during SARS-CoV-2 infection?
The host immune system produces a variety of regulatory molecules, including interferons, during a response to viral infection. Although previously considered...
Inflammatory attack comes from an unexpected source in rheumatoid arthritis
Researchers have pinpointed immune cells called natural killer cells as an unexpected source of inflammatory proteins that contribute to rheumatoid arthritis....
New nanoparticles help reduce inflammatory disease
Researchers from Washington State University have discovered a potential new treatment option for diseases associated with inflammation. The study, published...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter